John P. Butler - Jan 31, 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
CEO and President, Director
Signature
/s/ Carolyn Rucci, attorney-in-fact for John P. Butler
Stock symbol
AKBA
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 03:15 PM
Previous filing
Jun 16, 2022
Next filing
Mar 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +293K +20.84% $0.00 1.7M Jan 31, 2023 Direct F1, F2
holding AKBA Common Stock 59.9K Jan 31, 2023 Held by Dorothy Butler 2019 GRAT
holding AKBA Common Stock 100K Jan 31, 2023 Held By Dorothy Butler GRAT November 2019
holding AKBA Common Stock 59.9K Jan 31, 2023 Held by John Butler 2019 GRAT
holding AKBA Common Stock 100K Jan 31, 2023 Held By John Butler GRAT November 2019

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Appreciation Right Award $0 +635K $0.00 635K Jan 31, 2023 Common Stock 635K $0.63 Direct F3
transaction AKBA Stock Option (Right to buy) Award $0 +875K $0.00 875K Jan 31, 2023 Common Stock 875K $0.63 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2 Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2022 and 1,500 shares of the Issuer's common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.
F3 The stock appreciation rights ("SARs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The SARs will vest over four years: 25% of the SARs will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
F4 The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.